Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Corey Siegel

Gastroenterology Lebanon, NH Medical Doctor

NPI 1699798322 CMS profile 76568

1 Medical Center Dr, Lebanon, NH 03756

Open in the dashboard

General payments

$602,417

225 records reported · program years 2019–2025

Research payments

$3,945

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,303,493 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Corey Siegel of Lebanon, NH is reported in the CMS Open Payments database as having received $602,417 across 225 general payments and $3,945 in research payments paid to them. Separately, studies naming them as principal investigator received $1,303,493 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $44,549 29
2024 General $126,721 52
2024 Research $3,615 1
2023 General $90,938 51
2022 General $66,398 32
2022 Research $330 1
2021 General $130,217 20
2020 General $7,554 6
2019 General $136,040 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Corey Siegel
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Corey Siegel were reported at $44,549. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Corey Siegel Gastroenterology median Middle half National median
2019 $136,040 $417 $126–$1,100 $163
2020 $7,554 $224 $74–$624 $114
2021 $130,217 $352 $106–$1,054 $132
2022 $66,398 $448 $129–$1,270 $149
2023 $90,938 $533 $150–$1,390 $160
2024 $126,721 $605 $160–$1,606 $164
2025 $44,549 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $181,915 26 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $112,360 29 payments
  3. AbbVie, Inc. $61,578 51 payments
  4. Napo Pharmaceuticals Inc $51,000 17 payments
  5. Janssen Biotech, Inc. $46,493 39 payments
  6. Genzyme Corporation $35,111 9 payments
  7. Sebela Pharmaceuticals Inc. $28,000 4 payments
  8. Celltrion USA Inc. $20,061 13 payments
  9. E.R. Squibb & Sons, L.L.C. $19,535 6 payments
  10. Takeda Pharmaceutical Company, Limited $17,972 4 payments
  11. Other $28,391 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $367,054 106 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $116,219 17 payments
  3. Grant $50,000 1 payment
  4. Honoraria $33,924 9 payments
  5. Travel and Lodging $32,632 33 payments
  6. Food and Beverage $2,568 58 payments
  7. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. XELJANZ $81,114 13 payments
  2. Mytesi $51,000 17 payments
  3. TREMFYA $38,202 28 payments
  4. Entyvio Lower GI $18,138 8 payments
  5. ZYMFENTRA $18,011 11 payments
  6. ENTYVIO Internal Medicine $16,452 7 payments
  7. ZEPOSIA $13,385 4 payments
  8. STELARA $12,939 15 payments
  9. SKYRIZI $10,800 9 payments
  10. INFLECTRA $9,607 2 payments
  11. Other $25,227 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,615 1 payment
  2. Pfizer Inc. $330 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

378

Median for Gastroenterology: 569

Drug cost

$3,602,389

Median for Gastroenterology: $104,976

Branded share of claims

70.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Stelara Ustekinumab Brand 122 $3,129,330
Skyrizi On-Body Risankizumab-Rzaa Brand 11 $225,038
Humira(Cf) Pen Adalimumab Brand 17 $196,927
Mesalamine Generic 25 $27,849
Mesalamine Er Mesalamine Brand 13 $9,082
Balsalazide Disodium Generic 15 $7,586
Loperamide Loperamide Hcl Brand 20 $1,700
Esomeprazole Magnesium Generic 22 $1,493
Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine Brand 26 $995
Azathioprine Generic 13 $819

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$23,321

Medicare's payments for the services billed

Medicare patients

170

Average age 69

Services billed

345

94 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 38%
Depression 34%
Diabetes 27%
Ischemic heart disease 23%
Atrial fibrillation 20%
Cancer 19%
Chronic kidney disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $26,586
$26,586 — —
Mytesi
  • Napo Pharmaceuticals Inc $12,000
$12,000 — —
SKYRIZI
  • AbbVie, Inc. $2,400
$2,400 11 —
RINVOQ
  • AbbVie, Inc. $1,600
$1,600 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $452
$452 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record